TY - JOUR
T1 - Cancer development in patients hospitalised with systemic lupus erythematosus
T2 - A longitudinal population-level data linkage study
AU - Raymond, W.
AU - Preen, D.
AU - Keen, H.
AU - Inderjeeth, C.
AU - Nossent, J.
PY - 2022/6
Y1 - 2022/6
N2 - Background The association between systemic lupus erythematosus (SLE) and cancer risk is unclear.Objectives Describe the association between systemic lupus erythematosus (SLE) and the risk of cancer development and subsequent 5-year mortality in Western Australia (WA).Methods Population-level cohort study of SLE patients (n=2,111) and general population comparators (n=21,110) hospitalised between 1980–2014. SLE patients (identified by ICD-9-CM: 695.4, 710.0, and ICD-10-AM: L93.0, M32.0) were nearest matched (10:1) for age, sex, Aboriginality, and temporality. Follow-up was from timezero (index SLE hospitalisation) to cancer development, death or 31/12/2014. Using longitudinal linked health data, we determined the risk of cancer development and subsequent 5-year mortality between SLE patients and comparators with Cox proportional hazards regression models.Results SLE patients had similar multivariate-adjusted risk (aHR 1.03, 95%CI 0.93, 1.15; P=0.583) of cancer development. Cancer development risk was higher in SLE patients
AB - Background The association between systemic lupus erythematosus (SLE) and cancer risk is unclear.Objectives Describe the association between systemic lupus erythematosus (SLE) and the risk of cancer development and subsequent 5-year mortality in Western Australia (WA).Methods Population-level cohort study of SLE patients (n=2,111) and general population comparators (n=21,110) hospitalised between 1980–2014. SLE patients (identified by ICD-9-CM: 695.4, 710.0, and ICD-10-AM: L93.0, M32.0) were nearest matched (10:1) for age, sex, Aboriginality, and temporality. Follow-up was from timezero (index SLE hospitalisation) to cancer development, death or 31/12/2014. Using longitudinal linked health data, we determined the risk of cancer development and subsequent 5-year mortality between SLE patients and comparators with Cox proportional hazards regression models.Results SLE patients had similar multivariate-adjusted risk (aHR 1.03, 95%CI 0.93, 1.15; P=0.583) of cancer development. Cancer development risk was higher in SLE patients
KW - Rheumatology
U2 - 10.1136/annrheumdis-2022-eular.3999
DO - 10.1136/annrheumdis-2022-eular.3999
M3 - Abstract/Meeting Abstract
SN - 0003-4967
VL - 81
SP - 671
EP - 671
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
ER -